2018
DOI: 10.1136/bcr-2017-223965
|View full text |Cite
|
Sign up to set email alerts
|

Intraoperative intraluminal injection of N-acetylcysteine allowing treatment of distal intestinal obstruction syndrome without the need for enterotomy

Abstract: We describe a case of an 18-year-old man who suffers from cystic fibrosis and developed distal intestinal obstruction syndrome while being treated as an inpatient. Following failed medical management, we proceeded to laparotomy where the small bowel was decompressed with retrograde milking into the stomach, leaving a section of impacted stool in the distal ileum. N-acetylcysteine was injected into the bowel lumen proximal to the obstruction. This resulted in dissolution of the stool without the need for entero… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(6 citation statements)
references
References 13 publications
0
6
0
Order By: Relevance
“…DIOS can develop at any age; however, it occurs almost exclusively in patients over the age of 15 and peaks in young adults aged 20–25 years . There is a varying incidence observed in the literature that ranges from 2.3 to 11.3 episodes/1000 patient‐years internationally, and is higher in those aged 20–25 years at 35.5 episodes/1000 patient‐years . A gradual increase in prevalence is being observed, initially less than 7% and now greater then 40%, likely reflecting the increasing life expectancy of CF patients …”
Section: Incidence and Prevalencementioning
confidence: 99%
See 4 more Smart Citations
“…DIOS can develop at any age; however, it occurs almost exclusively in patients over the age of 15 and peaks in young adults aged 20–25 years . There is a varying incidence observed in the literature that ranges from 2.3 to 11.3 episodes/1000 patient‐years internationally, and is higher in those aged 20–25 years at 35.5 episodes/1000 patient‐years . A gradual increase in prevalence is being observed, initially less than 7% and now greater then 40%, likely reflecting the increasing life expectancy of CF patients …”
Section: Incidence and Prevalencementioning
confidence: 99%
“…In patients with a severe CF genotype, or class I–III mutations where there is no functional CFTR protein, there is an association between the development of DIOS and the degree of impairment in chloride secretion . However, it is not an absolute association as patients with a mild genotype may still suffer from DIOS …”
Section: Risk Factorsmentioning
confidence: 99%
See 3 more Smart Citations